Experience of guselkumab usage in the treatment of patients with psoriatic arthritis in real clinical practice

The article presents an analysis of literature on the efficacy and safety of a new biologic disease modifying antirheumatic drug usage, the interleukin 23 inhibitor – guselkumab (GUS) – in the treatment of patients with psoriatic arthritis (PsA). Two own clinical observations of GUS therapy are desc...

Full description

Saved in:
Bibliographic Details
Main Authors: E. Yu. Loginova, Yu. L. Korsakova, T. V. Korotaeva
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2021-10-01
Series:Современная ревматология
Subjects:
Online Access:https://mrj.ima-press.net/mrj/article/view/1204
Tags: Add Tag
No Tags, Be the first to tag this record!